Profile data is unavailable for this security.
About the company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-37.56m
- Incorporated1997
- Employees20.00
- LocationNuCana PLCLochside House, 3 Lochside WayEDINBURGH EH12 9DTUnited KingdomGBR
- Phone+44 131 248 3660
- Fax+44 131 248 3001
- Websitehttps://www.nucana.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allarity Therapeutics Inc | 0.00 | -15.31m | 13.59m | 6.00 | -- | 1.13 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 14.62m | 17.00 | -- | 5.69 | -- | 3.49 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 14.64m | 9.00 | -- | -- | -- | 37.55 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Curis Inc | 11.65m | -36.56m | 14.87m | 33.00 | -- | -- | -- | 1.28 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 15.03m | 5.00 | -- | 1.70 | -- | -- | -0.638 | -0.638 | 0.00 | 0.1472 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -37.56m | 15.20m | 20.00 | -- | 0.4296 | -- | -- | -7,212.13 | -7,212.13 | 0.00 | 4.93 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 15.34m | 7.00 | 0.068 | 3.01 | -- | 5.39 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.42m | 360.00 | -- | -- | -- | 0.0107 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 15.47m | 2.00 | -- | 1.90 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.43m | 15.89m | 23.00 | -- | 0.2047 | -- | -- | -3.84 | -3.84 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -32.10 | -29.86 | -52.00 | -35.19 | -- | -- | -- | -- | 0.1257 | -244.30 | 0.0127 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 16.24m | 3.00 | -- | 1.57 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 16.40m | 4.00 | -- | 0.433 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -18.50m | 16.70m | 13.00 | -- | 96.91 | -- | -- | -0.4809 | -0.4809 | 0.00 | 0.0026 | 0.00 | -- | -- | 0.00 | -192.59 | -- | -636.43 | -- | -- | -- | -- | -- | -- | -27.09 | 0.9734 | -- | -- | -- | 41.44 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Glass Jacobson Investment Advisors LLCas of 31 Dec 2025 | 15.00k | 0.79% |
| Jane Street Capital LLCas of 31 Dec 2025 | 11.33k | 0.59% |
| FNY Investment Advisers LLCas of 31 Dec 2025 | 10.00k | 0.53% |
| RhumbLine Advisers LPas of 31 Dec 2025 | 4.91k | 0.26% |
| UBS Securities LLCas of 31 Dec 2025 | 3.65k | 0.19% |
| Tower Research Capital LLCas of 30 Sep 2025 | 1.23k | 0.06% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 383.00 | 0.02% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 103.00 | 0.01% |
| Jump Execution LLCas of 30 Jun 2025 | 83.00 | 0.00% |
| HRK LUNIS AGas of 30 Sep 2024 | 44.00 | 0.00% |
